The Senate Health, Education, Labor & Pensions Committee today held a examining the administration鈥檚 blueprint to lower prescription drug prices. Health and Human Services Secretary Alex Azar testified on steps the agency is taking to implement the blueprint. For example, Azar noted, the Centers for Medicare & Medicaid Services recently unveiled updates to its drug-pricing dashboard and warned Medicare Part D plan sponsors that their contracts with pharmacies should not prevent the pharmacist from telling customers when they can get a better deal on a drug by paying cash; and the Food and Drug Administration also recently began publicly identifying drug companies suspected of blocking access to samples needed to test generic drugs. Among other actions, he said HHS is working to require drug companies to include their list price in their television commercials; give Medicare Part D plans market-based tools to negotiate better deals with drug companies; and 鈥渂ring negotiation to Medicare Part B.鈥

Related News Articles

Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy鈥
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation鈥
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at鈥
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and鈥
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District鈥